How neutrophils trap and kill bacteria using new methods
Neutrophil Extracellular Traps and Host Immunity
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11043391
This study is looking at how a common immune cell helps fight bacteria in people with Chronic Granulomatous Disease (CGD) and is testing if the drug Tamoxifen can help these patients make more of these helpful traps to better fight infections.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11043391 on ClinicalTrials.gov |
What this research studies
This research investigates the role of neutrophils, a type of immune cell, in trapping and killing bacteria through a process called NETosis, which forms extracellular traps. The study focuses on patients with Chronic Granulomatous Disease (CGD), who have difficulty generating these traps due to genetic mutations. Researchers are exploring how the FDA-approved drug Tamoxifen can stimulate NET formation in these patients, potentially offering a new treatment approach. By understanding the mechanisms behind this process, the research aims to improve immune responses against bacterial infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Chronic Granulomatous Disease or similar immune deficiencies.
Not a fit: Patients without immune deficiencies or those not affected by bacterial infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with weakened immune systems, particularly those with CGD, enhancing their ability to fight infections.
How similar studies have performed: Previous studies have shown promise in using similar approaches to enhance immune responses, but this specific pathway involving Tamoxifen is relatively novel.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHARMA, JYOTIKA — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: SHARMA, JYOTIKA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: acute infection, Airway Disease, Anti-Cancer Agents, anti-cancer drug